News
May 21, 2018 β Complete pulmonary vein isolation (PVI) was achieved in more than 99 percent of patients in a first-in ...
May 21, 2018
News
May 21, 2018 β The available electrophysiology catheter ablation technologies are not designed for use in the ...
May 21, 2018
Blog | HRS
Electrophysiology is one of the most rapidly-growing areas of healthcare. That may be why itβs the focus of so many ...
May 21, 2018Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024
News | Thrombectomy Devices
Medtronic and the U.S. Food and Drug Administration (FDA) announced a Class I Urgent Medical Device Recall of the MindFrame Capture LP revascularization device on account of a risk of the delivery wire breaking or separating during use.
May 21, 2018
Technology
May 21, 2018 β Cardiology medical device reprocessing company Innovative Health recently received U.S. Food and Drug ...
May 21, 2018
News | EP Lab
May 21, 2018 β A recent study published in Heart and Vessels has found that the use of the Baylis Medical NRG ...
May 21, 2018Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
News | Leads Implantable Devices
Data on the effectiveness of cardiac resynchronization therapy (CRT) in patients with non-left bundle branch block (non-LBBB) is limited and when available has been shown to be suboptimal compared to LBBB patients. A new study presented at the 2018 Heart Rhythm Society (HRS) Scientific Sessions, May 9-12 in Boston, compared the effects of targeting the region of increased electrical delay (QLV approach) for left ventricular (LV) lead location to a standard of care (SOC) anatomical implant approach in non-LBBB patients. The comparison was assessed on the Clinical Composite Score (CCS) after 12 months of follow-up.
May 18, 2018
News | Heart Failure
In a new study, cardiac contractility modulation (CCM) therapy was confirmed to significantly improve exercise tolerance (ET) and quality of life (QoL) for patients with persistent symptomatic heart failure and an ejection fraction between 25 and 45 percent. Results of the prospective FIX-HF-5C Study were presented at the 2018 Heart Rhythm Society (HRS) Scientific Sessions, May 9-12 in Boston.
May 18, 2018
Feature | Left Atrial Appendage (LAA) Occluders
May 18, 2018 β Left atrial appendage closure (LAAC) with the transcatheter Watchman device prevents thromboembolism from ...
May 18, 2018Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
News | Atrial Fibrillation
May 18, 2018 β Catheter ablation for atrial fibrillation (AF) in patients with heart failure in the CASTLE-AF Trial was ...
May 18, 2018
May 18, 2018 β Nearly half of patients prescribed warfarin and just under one third of those using newer direct oral ...
May 18, 2018
News | EP Lab
May 18, 2018 β A significant number of patients with symptomatic premature ventricular contractions (PVCs) have ...
May 18, 2018Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023
News | Atrial Fibrillation
May 18, 2018 β Three year results of a study found injection of botulinum toxin into epicardial fat pads in patients ...
May 18, 2018
Feature | HRS | Dave Fornell
Here is an aggregation of all the news and late-breaking studies presented at the 2018 Heart Rhythm Society (HRS) ...
May 18, 2018
Feature | Atrial Fibrillation
May 16, 2018 β The first results of the randomized, multicenter, long-term, international CABANA clinical trial were ...
May 17, 2018Β© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now